US FDA clarification on Makena boosts KV shares
This article was originally published in Scrip
Executive Summary
After being beaten up by members of Congress, the American College of Obstetricians and Gynecologists and others for the high price of its preterm birth drug Makena (hydroxyprogesterone caproate injection), KV Pharmaceutical was quick to ensure investors saw the latest word from the US FDA, which backed use of the agency-approved medicine over compounded formulations of the active ingredient in a notice posted on its website.